Company Overview - Tanshen Nano Technology (Quzhou) Co., Ltd. specializes in the research and development of Atomic Force Microscopy (AFM) probes and has recently completed a new round of equity financing, raising over 10 million yuan from Quzhou Greenstone New Materials Equity Investment Partnership and Hangzhou Defu Equity Investment Co., Ltd. [1][3] - The company was established in 2016 and is located in Quzhou, Zhejiang Province. It has accumulated years of technology and process expertise in micro-nano processing, achieving a leading position in key metrics such as probe curvature radius, aspect ratio, and lifespan [1][3]. Financing Details - The recent financing round is categorized as Pre-A/A round, with funds primarily aimed at optimizing the mass production process of probes, enhancing product stability and yield. Additionally, the funds will support the development of a full range of AFM probes and the establishment of new production lines [1][3]. Industry Context - AFM is an essential high-precision detection instrument in various fields, including nanotechnology, materials science, semiconductor industry, and life sciences. It plays a critical role in semiconductor manufacturing by ensuring quality through precise scanning of chips [2][4]. - AFM probes, as core consumable components of AFM, have high usage frequency and strong repurchase attributes. Historically, they have relied on imports, which are costly and subject to supply constraints, leading to cost and supply chain risks in research and industrial applications [2][4]. - The trend towards domestic production and self-sufficiency in scientific instruments is creating a clear space for domestic alternatives in the AFM probe market, which is characterized by small volume, high added value, and high repurchase rates. This domestic production process is expected to drive the development of related supporting industrial chains [2][4].

Core Viewpoint - Anypu successfully completed nearly 100 million RMB in Series B financing, which will be used to enhance the performance and production capacity of its core mass spectrometry products, deepen application exploration in various fields, and accelerate market penetration [2][4]. Financing Details - The Series B financing was led by Boyuan Capital and BGI Songhe, with continued investment from existing shareholder Yuansheng Venture Capital and rapid implementation from Haineng Technology [4][5]. - The financing will focus on three main areas: improving the performance and production capacity of core products such as triple quadrupole liquid mass spectrometers, high-resolution mass spectrometers, and online mass spectrometers; deepening the application exploration of mass spectrometry technology in research, food and drug monitoring, chemical industry, and semiconductor industries; and accelerating market penetration to meet the rapidly growing domestic demand for high-end analytical testing [5]. Company Strategy and Market Position - Anypu has consistently focused on the independent research and manufacturing of high-end mass spectrometry instruments since its establishment. The product line includes single quadrupole, triple quadrupole gas/liquid chromatography-mass spectrometry systems, portable small molecule mass spectrometers, and various forms such as laboratory benchtop, vehicle-mounted, portable, and online systems [6]. - The company’s development plan aligns closely with national strategies such as "Quality Power" and "Independent Control of Scientific Research Instruments." Anypu aims to enhance core performance metrics like resolution and sensitivity while improving reliability and long-term stability [6]. Investor Confidence - Investors have expressed strong confidence in Anypu's technological strength and market prospects. The team from BGI Songhe Fund noted that Anypu's breakthroughs in high-end mass spectrometry instruments and product capabilities are impressive, with products now competitive with international brands [7][8]. - Boyuan Capital highlighted that Anypu's product portfolio aligns well with national strategic directions, and the company is expected to quickly capture incremental market opportunities under the dual drivers of technological innovation and industrial upgrading [8]. - Haineng Technology emphasized Anypu's deep technical and product accumulation in the mass spectrometry field, recognizing significant market growth potential in semiconductors and life sciences [8]. Market Demand - There is an increasing urgency for domestic high-end scientific instruments to be independently controllable and for supply chain security. The demand for mass spectrometry analysis technology from downstream strategic emerging industries continues to grow [8]. - Anypu is poised to seize new opportunities for rapid development due to its superior performance, diverse mass spectrometry products, extensive application coverage, and comprehensive advantages that align with local incremental demand [8].

Core Insights - New Zhi Bio, the first stock in life science instruments listed on the Beijing Stock Exchange, emphasizes the importance of innovation and capital support for small and medium-sized enterprises [2][3] Company Overview - New Zhi Bio is one of the earliest companies in China focused on the research, production, and sales of life science instruments, with over 20 product lines and more than 200 product models [3] - The company has transitioned from a laboratory equipment supplier to a comprehensive service provider covering the entire process from experimentation to mass production [3][4] Product Development - The company continues to innovate in traditional product lines while expanding new product lines, including customized models for various industries, maintaining a stable customized business ratio of over 20% [3][4] - New Zhi Bio has achieved significant technological breakthroughs in ultrasonic processing and freeze-drying, enabling the development of industrial-grade products [3] Strategic Expansion - The company is focusing on integrating capital to accelerate industrial consolidation, exemplified by the acquisition of a 55% stake in Ningbo Afus Constant Temperature Company to enhance its industrial temperature control solutions [4] - New Zhi Bio is shifting its strategic focus towards high-end instruments and global expansion, leveraging the increasing emphasis on independent control of scientific instruments at the national level [5][6] Market Positioning - The company has reached a critical stage in achieving independent control over life science instruments, with some products nearing or surpassing international advanced levels [6] - New Zhi Bio plans to establish a localized service network for its overseas markets, moving from reliance on foreign distributors to a direct service model [6] Capital Market Insights - The Beijing Stock Exchange has played a crucial role in supporting innovative small and medium-sized enterprises, fostering a development pattern that balances quantity and quality [7] - The listing has enhanced the company's brand influence, talent attraction, and shareholder structure, allowing it to compete effectively in the talent market [7] - New Zhi Bio aims to become a "research supermarket" and a provider of comprehensive solutions, leveraging opportunities for collaboration with leading companies in niche markets [7]